Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with risperidone (low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Blepharospasm‐specific severity ( · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse events (reported at any time) (2 RCT, 169 participants) · adults with blepharospasm
Botulinum toxin type A showed no clear difference in adverse events (reported at any time) (2 RCT, 169 participants) compared with placebo (low certainty).
1 finding from 1 review
RR 1.18 [0.87, 1.6]
Studies not reported
Low
Subjective evaluation of the treatments by participants · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
High
Frequency of blepharospasm‐specific involuntary movements ( · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life · adults with blepharospasm
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tolerability (number of dropouts; reported at any time) (2 RCT, 169 participants) · adults with blepharospasm
Botulinum toxin type A showed no clear difference in tolerability (number of dropouts; reported at any time) (2 RCT, 169… compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.44 [0.31, 6.79]
Studies not reported
Moderate
Duration of effect (when effects started to wane) · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
Low
50% or greater reduction in seizure frequency · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).
1 finding from 1 review
Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).
1 finding from 1 review
Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).
1 finding from 1 review
Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant generalised tonic‐clonic seizures
Add‐on lamotrigine may leads to higher 50% or greater reduction in seizure frequency compared with placebo (low certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes seizure freedom (i.e. total cessation of seizure activity) compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes treatment withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review